FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1990281680> ?p ?o ?g. }

• W1990281680 endingPage "639" @default.
• W1990281680 startingPage "639" @default.
• W1990281680 abstract "Benefit of intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme disease Raphael B Stricker1,3, Allison K DeLong2, Christine L Green1,3, Virginia R Savely1,3, Stanley N Chamallas1,4, Lorraine Johnson1,31International Lyme and Associated Diseases Society, Bethesda, MD, USA; 2Center for Statistical Sciences, Brown University, Providence, RI, USA; 3California Lyme Disease Association, Marysville, CA, USA; 4QMedRx Inc, Maitland, FL, USABackground: We have shown previously that extended intravenous antibiotic therapy is associated with low morbidity and no mortality in patients referred for treatment of neurologic Lyme disease. In this study, we evaluated the benefit of extended intravenous antibiotic therapy in patients with symptoms of neurologic Lyme disease.Methods: Patients with significant neurologic symptoms and positive testing for Borrelia burgdorferi were treated with intravenous antibiotics, and biweekly evaluation of symptom severity was performed using a six-level ordinal scale. Four symptoms were selected a priori as primary outcome measures in the study, ie, fatigue, cognition, myalgias, and arthralgias. Patients were placed into five groups according to time on treatment (1–4, 5–8, 9–12, 13–24, and 25–52 weeks), and changes in the primary symptoms as a function of time on treatment were analyzed using a mixed-effects proportional odds model.Results: Among 158 patients with more than one follow-up visit who were monitored for up to 1 year, there were on average 6.7 visits per person (median 5, range 2–24). The last follow-up day was on average 96 days after enrollment (median 69, range 7–354 days), corresponding to the length of antibiotic therapy. Each primary symptom was significantly improved at one or more time points during the study. For cognition, fatigue, and myalgias, the greatest improvement occurred in patients on the longest courses of treatment (25–52 weeks) with odds ratios (OR) for improvement of 1.97 (P = 0.02), 2.22 (P < 0.01), and 2.08 (P = 0.01), respectively. In contrast, arthralgias were only significantly improved during the initial 1–4 weeks of therapy (OR: 1.57, P = 0.04), and the beneficial effect of longer treatment did not reach statistical significance for this symptom.Conclusion: Prolonged intravenous antibiotic therapy is associated with improved cognition, fatigue, and myalgias in patients referred for treatment of neurologic Lyme disease. Treatment for 25–52 weeks may be necessary to obtain symptomatic improvement in these patients.Keywords: Lyme disease, Borrelia burgdorferi, intravenous antibiotics, neurologic symptoms" @default.
• W1990281680 created "2016-06-24" @default.
• W1990281680 creator A5000017106 @default.
• W1990281680 creator A5007344354 @default.
• W1990281680 creator A5015056311 @default.
• W1990281680 creator A5045921776 @default.
• W1990281680 creator A5055307587 @default.
• W1990281680 creator A5089016460 @default.
• W1990281680 date "2011-09-01" @default.
• W1990281680 modified "2023-09-26" @default.
• W1990281680 title "Benefit of intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme disease" @default.
• W1990281680 cites W1553325804 @default.
• W1990281680 cites W2003202991 @default.
• W1990281680 cites W2004167492 @default.
• W1990281680 cites W2031589732 @default.
• W1990281680 cites W2048739984 @default.
• W1990281680 cites W2061126046 @default.
• W1990281680 cites W2068619958 @default.
• W1990281680 cites W2069905512 @default.
• W1990281680 cites W2074409567 @default.
• W1990281680 cites W2082271214 @default.
• W1990281680 cites W2087160851 @default.
• W1990281680 cites W2093995575 @default.
• W1990281680 cites W2100482235 @default.
• W1990281680 cites W2100584234 @default.
• W1990281680 cites W2106077838 @default.
• W1990281680 cites W2108126937 @default.
• W1990281680 cites W2111976364 @default.
• W1990281680 cites W2113413884 @default.
• W1990281680 cites W2118904459 @default.
• W1990281680 cites W2120808607 @default.
• W1990281680 cites W2126060212 @default.
• W1990281680 cites W2130345017 @default.
• W1990281680 cites W2133866452 @default.
• W1990281680 cites W2141152593 @default.
• W1990281680 cites W2143628550 @default.
• W1990281680 cites W2153223268 @default.
• W1990281680 cites W2157394313 @default.
• W1990281680 cites W2163586341 @default.
• W1990281680 cites W2168281198 @default.
• W1990281680 cites W2169762361 @default.
• W1990281680 cites W2171969385 @default.
• W1990281680 cites W21916553 @default.
• W1990281680 cites W2335266012 @default.
• W1990281680 cites W2406423760 @default.
• W1990281680 cites W2610257217 @default.
• W1990281680 cites W3188147735 @default.
• W1990281680 cites W52696524 @default.
• W1990281680 cites W199901113 @default.
• W1990281680 doi "https://doi.org/10.2147/ijgm.s23829" @default.
• W1990281680 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3177589" @default.
• W1990281680 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21941449" @default.
• W1990281680 hasPublicationYear "2011" @default.
• W1990281680 type Work @default.
• W1990281680 sameAs 1990281680 @default.
• W1990281680 citedByCount "23" @default.
• W1990281680 countsByYear W19902816802012 @default.
• W1990281680 countsByYear W19902816802013 @default.
• W1990281680 countsByYear W19902816802014 @default.
• W1990281680 countsByYear W19902816802015 @default.
• W1990281680 countsByYear W19902816802016 @default.
• W1990281680 countsByYear W19902816802018 @default.
• W1990281680 countsByYear W19902816802020 @default.
• W1990281680 countsByYear W19902816802021 @default.
• W1990281680 crossrefType "journal-article" @default.
• W1990281680 hasAuthorship W1990281680A5000017106 @default.
• W1990281680 hasAuthorship W1990281680A5007344354 @default.
• W1990281680 hasAuthorship W1990281680A5015056311 @default.
• W1990281680 hasAuthorship W1990281680A5045921776 @default.
• W1990281680 hasAuthorship W1990281680A5055307587 @default.
• W1990281680 hasAuthorship W1990281680A5089016460 @default.
• W1990281680 hasBestOaLocation W19902816801 @default.
• W1990281680 hasConcept C126322002 @default.
• W1990281680 hasConcept C159654299 @default.
• W1990281680 hasConcept C187212893 @default.
• W1990281680 hasConcept C203014093 @default.
• W1990281680 hasConcept C2776307562 @default.
• W1990281680 hasConcept C2777553296 @default.
• W1990281680 hasConcept C2779134260 @default.
• W1990281680 hasConcept C2779159148 @default.
• W1990281680 hasConcept C501593827 @default.
• W1990281680 hasConcept C71924100 @default.
• W1990281680 hasConcept C86803240 @default.
• W1990281680 hasConcept C89423630 @default.
• W1990281680 hasConceptScore W1990281680C126322002 @default.
• W1990281680 hasConceptScore W1990281680C159654299 @default.
• W1990281680 hasConceptScore W1990281680C187212893 @default.
• W1990281680 hasConceptScore W1990281680C203014093 @default.
• W1990281680 hasConceptScore W1990281680C2776307562 @default.
• W1990281680 hasConceptScore W1990281680C2777553296 @default.
• W1990281680 hasConceptScore W1990281680C2779134260 @default.
• W1990281680 hasConceptScore W1990281680C2779159148 @default.
• W1990281680 hasConceptScore W1990281680C501593827 @default.
• W1990281680 hasConceptScore W1990281680C71924100 @default.
• W1990281680 hasConceptScore W1990281680C86803240 @default.
• W1990281680 hasConceptScore W1990281680C89423630 @default.
• W1990281680 hasLocation W19902816801 @default.
• W1990281680 hasLocation W19902816802 @default.

• next